window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 17, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

cryo-EM

  • Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain

    FairJourney Bio opens cryo-EM facility in San Diego for antibody discovery

    FairJourney Bio has opened a cryo-EM structural biology facility in [...]

    May 5, 2026
  • Digital & Data,Drug Discovery & Development,Manufacturing & Supply Chain

    Thermo Fisher launches Glacios 3 cryo-TEM to expand access to structural biology imaging

    Thermo Fisher Scientific has launched the Thermo Scientific Glacios 3 [...]

    May 5, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development

    Nuclera and leadXpro partner on AI-guided workflow for membrane protein drug discovery

    Nuclera and leadXpro have entered a scientific partnership to develop [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ZoBio launches DNA-encoded library hit discovery service for difficult drug targets
    Categories: Biotech & Pharma Business, Drug Discovery & Development
  • Elicio misses Phase 2 endpoint but advances Phase 3 plan for pancreatic cancer immunotherapy
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Context reports 29% response rate for CTIM-76 in platinum-resistant ovarian cancer
    Categories: Advanced Therapies, Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top